|
Characteristic
|
No. of patients (%) (N = 34)
|
|---|
|
Age (mean)
|
60 years
|
|
Smoking history (median)
|
35 pack-years
|
|
Gender
| |
|
Male
|
27 (79%)
|
|
Female
|
7 (21%)
|
|
AJCC 7th edition Stage
| |
|
III
|
3 (9%)
|
|
IVa
|
28 (82%)
|
|
IVb
|
3 (9%)
|
|
AJCC 8th edition stage
| |
|
II (P16 positive)
|
17 (50%)
|
|
III (P16 positive)
|
4 (12%)
|
|
III (p16 negative)
|
3 (9%)
|
|
IVa (p16 negative)
|
10 (29%)
|
|
T Classification
| |
|
T1
|
2 (6%)
|
|
T2
|
15 (44%)
|
|
T3
|
11 (32%)
|
|
T4a
|
5 (15%)
|
|
T4b
|
1 (3%)
|
|
N Classification
| |
|
N0
|
1 (3%)
|
|
N1
|
5 (15%)
|
|
N2a
|
5 (15%)
|
|
N2b
|
14 (41%)
|
|
N2c
|
9 (26%)
|
|
Primary site
| |
|
Tonsil
|
19 (56%)
|
|
Base of tongue
|
13 (38%)
|
|
Pharyngeal wall
|
1 (3%)
|
|
Soft palate
|
1 (3%)
|
|
Mean boost volume
|
54 cc (range 13–185 cc)
|
|
8 Gy SRS boost
|
11 (32%)
|
|
10 Gy SRS boost
|
16 (47%)
|
|
5 Gy × 2 SRS boost
|
7 (21%)
|
|
HPV status
| |
|
HPV-positive smokers
|
21 (62%)
|
|
HPV-negative
|
13 (38%)
|
|
Chemotherapy
| |
|
Cisplatin
|
27 (79%)
|
|
Cetuximab
|
1 (3%)
|
|
Carboplatin paclitaxel
|
1 (3%)
|
|
Cisplatin followed by carboplatin and paclitaxel
|
4 (12%)
|
|
Unknown
|
1 (3%)
|
